Welcome to our dedicated page for Surrozen SEC filings (Ticker: SRZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Surrozen, Inc. (SRZN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Surrozen uses these filings to report financial results, material events, executive appointments, collaboration changes, and other information relevant to its development of Wnt pathway–modulating therapeutics for severe eye diseases.
Current reports on Form 8-K are an important source of timely updates for SRZN. For example, Surrozen has filed 8-Ks to announce quarterly financial results, describe the appointment of a Chief Financial Officer and associated compensation arrangements, and disclose the termination of a collaboration agreement with TCGFB, Inc. for antibody discovery services. These filings often reference attached press releases that provide more detailed narrative on business performance and pipeline progress.
Investors can also use Surrozen’s periodic reports, such as its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, to review consolidated financial statements, research and development spending, and risk factor discussions. The company’s forward-looking statements in press releases explicitly point readers to these reports for a fuller description of risks related to its discovery, preclinical and potential clinical activities, funding needs, and collaboration structures.
On Stock Titan, Surrozen’s SEC filings are complemented by AI-powered summaries that highlight key points from lengthy documents, helping users quickly identify items such as revenue sources, operating expenses, non-cash fair value changes, and material agreements. Filings related to equity compensation and inducement grants under Nasdaq Listing Rule 5635(c)(4) can help users understand Surrozen’s use of stock options and warrants, while 8-K items on collaborations and licenses provide insight into related-party transactions and strategic partnerships, including the Boehringer Ingelheim agreement for SZN-413. Together, these filings offer a structured view of Surrozen’s financial condition, governance decisions, and development activities.
Surrozen, Inc. insider filing shows fund-level share purchases linked to director and 10% owner Tim Kutzkey. On January 6, 2026, The Column Group III, LP bought 7,097 shares of Surrozen common stock at $19.8872 per share, and The Column Group III-A, LP bought an additional 8,003 shares at the same price. These holdings are reported as indirect ownership for Kutzkey through the Column Group entities.
After the transactions, The Column Group III, LP is shown with 876,557 shares and The Column Group III-A, LP with 989,893 shares of Surrozen common stock, reported as indirectly owned. A related vehicle, The Column Group Opportunity III, LP, is reported with 344,827 shares indirectly owned. The filing notes that the general partner entities and managing partners, including Kutzkey, disclaim beneficial ownership of these securities except to the extent of their pecuniary interest.
Surrozen, Inc. executive Yang Li, Executive Vice President of Research, reported acquiring additional company stock through an employee plan. On 12/15/2025, Li acquired 1,666 shares of Surrozen common stock at $8.11 per share under the Surrozen, Inc. 2021 Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(d) and Rule 16b-3(c).
Following this purchase, Li beneficially owns 14,709 shares directly, plus 351 shares held indirectly for a daughter and 351 shares held indirectly for a son, showing an increased personal stake in Surrozen’s equity.
Surrozen, Inc.'s Chief Operating Officer, Charles Williams, reported buying 1,666 shares of common stock on 12/15/2025 at $8.11 per share. This purchase brought his directly owned stake to 11,048 shares.
He is voluntarily reporting these shares, which were acquired under Surrozen's 2021 Employee Stock Purchase Plan. The transaction is noted as exempt from certain short-swing profit rules under Rule 16b-3(d) and Rule 16b-3(c), indicating a routine employee stock plan purchase by a senior executive.
Surrozen, Inc. reported an insider purchase by Chief Executive Officer and director Craig C. Parker. On 12/15/2025 he acquired 1,553 shares of Surrozen common stock at $8.11 per share, in a transaction made under the Surrozen, Inc. 2021 Employee Stock Purchase Plan and noted as exempt under Rule 16b-3(d) and Rule 16b-3(c). After this transaction, he beneficially owns 8,577 shares held directly.
Surrozen, Inc. (SRZN)
The Column Group entities report their holdings as indirect beneficial owners, with their general partners and managing members, including Surrozen director Tim Kutzkey, disclaiming beneficial ownership except to the extent of their pecuniary interest. The report is filed jointly by multiple related investment vehicles, reflecting a significant, coordinated ownership position in Surrozen.
Surrozen, Inc. (SRZN) reported an insider equity grant. The company’s Chief Financial Officer received an employee stock option for 50,000 shares on 11/12/2025 with an exercise price of $12.94 and an expiration date of 11/11/2035.
The award vests 25% on the first anniversary of the vesting commencement date, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continuous service. Following this grant, the reporting person holds 50,000 derivative securities, reported as directly owned.
Surrozen, Inc. (SRZN) filed a Form 3 disclosing the initial beneficial ownership of its Chief Financial Officer, Andrew Pedrum Maleki. The filing states that no securities are beneficially owned by the reporting person.
The report reflects an event date of 11/12/2025 and includes an Exhibit 24 Power of Attorney. The filing was made by one reporting person in the capacity of Chief Financial Officer.
Surrozen, Inc. filed its quarterly report for the three months ended September 30, 2025, detailing a biotechnology business focused on Wnt‑pathway therapeutics.
Q3 results show total revenue of
The balance sheet reflects total assets of
Surrozen (SRZN) appointed Andrew Maleki as Chief Financial Officer, effective November 12, 2025, and furnished a press release with results for the quarter ended September 30, 2025.
Maleki’s offer includes a base salary of $385,000, an annual bonus target of 40% of base salary starting in 2026, and a stock option for 50,000 shares vesting 25% after one year, then monthly in equal installments over the next three years. If terminated without cause, he is eligible for nine months of base salary and benefits. If terminated in connection with a change in control, he is eligible for 12 months of base salary, 100% of target bonus, 12 months of benefits, and full equity vesting.
Charles Williams will cease serving as CFO and continue as Chief Operating Officer and Secretary.
Surrozen, Inc. (SRZN) reported that TCGFB, Inc. elected to terminate their Collaboration Agreement. The notice was delivered on October 14, 2025, with termination effective November 13, 2025, and no termination penalties for either party.
Under the agreement, Surrozen provided antibody discovery services while TCGFB owned all TGF-β product intellectual property. In return, TCGFB agreed to pay Surrozen up to $6.0 million in the aggregate, plus third-party costs, and issued a warrant exercisable for up to 3.4 million TCGFB common shares at an exercise price of $0.0001 per share, subject to vesting conditions.
The arrangement was a related party transaction because entities affiliated with The Column Group hold more than 5% of Surrozen’s common stock and Dr. Kutzkey, a Surrozen director, serves as Managing Partner of The Column Group.